Product Information
LO-ZUMANDIMINE 3 MG-0.02 MG TB is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1909 per EA under NDC 59651002988. Its NADAC has been published 372 times since Aug 21, 2019.
FDA first approved this application on Feb 27, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Aurobindo Pharma LimitedNDC
59651002988
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA209632FDA Approved
2/27/2018
TE Code
AB
On Market Since
2/27/2018
Price Statistics
The NADAC for LO-ZUMANDIMINE 3 MG-0.02 MG TB has been published 372 times since Aug 21, 2019, and over the history we have for it it has declined 57.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1909 per EA |
|---|---|
| All-time high | $0.4650 (Sep 16, 2020) |
| All-time low | $0.1278 (Nov 20, 2024) |
| 52-week high | $0.1933 |
| 52-week low | $0.1538 |
| Median price | $0.2848 |
| Average price | $0.2869 |
| Largest weekly change | -32.1% (Nov 20, 2024) |
| Weeks tracked | 372 |
| Tracking since | Aug 21, 2019 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 21% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Drospirenone and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LO-ZUMANDIMINE 3 MG-0.02 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for LO-ZUMANDIMINE 3 MG-0.02 MG TB, manufactured by Aurobindo Pharma Limited, is $0.1909 per EA (NDC 59651002988), effective Sep 30, 2026.
How has the price of LO-ZUMANDIMINE 3 MG-0.02 MG TB changed over time?
Over the history we have for it, the NADAC for LO-ZUMANDIMINE 3 MG-0.02 MG TB has declined 57.1%. It has been tracked across 372 weekly CMS publications since Aug 21, 2019.
What are the highest and lowest recorded NADAC prices for LO-ZUMANDIMINE 3 MG-0.02 MG TB?
Since Aug 21, 2019, the NADAC for LO-ZUMANDIMINE 3 MG-0.02 MG TB has ranged from a low of $0.1278 (Nov 20, 2024) to a high of $0.4650 (Sep 16, 2020), with a median of $0.2848 per EA.
Are there cheaper alternatives to LO-ZUMANDIMINE 3 MG-0.02 MG TB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ZUMANDIMINE 3 MG-0.03 MG TAB, is $0.1511 per EA — about 21% below LO-ZUMANDIMINE 3 MG-0.02 MG TB.
Who manufactures LO-ZUMANDIMINE 3 MG-0.02 MG TB?
LO-ZUMANDIMINE 3 MG-0.02 MG TB (NDC 59651002988) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.